|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
IBC's The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics | ||||||||||||||||
July 17, 2003 | ||||||||||||||||
IBC Life Sciences, Sheraton Premier at Tysons Corner, Vienna, VA November 12-14, 2003 Learn to utilize post-translational changes for advancing your therapeutic protein while precluding expensive setbacks due to unnecessary modifications. IBC has gathered industry and academic leaders to share their diverse experience and proposed solutions for challenges in post-translational and chemical modifications of recombinant therapeutic proteins which occur during production, manufacturing and analysis of therapeutics. Plus, take in a short course on Immunogenicity of Recombinant Biological Therapeutics while your there! For full conference details and to register, visit www.LifeSciencesInfo.com/PTM. |
||||||||||||||||
Organized by: | IBC Life Sciences | |||||||||||||||
Invited Speakers: | Keynote Address: "Immunogenicity of Biological Therapeutics and Potential Approaches to Tolerance Induction" |
|||||||||||||||
Deadline for Abstracts: | - | |||||||||||||||
Registration: | Phone: (508) 616-5550 x1004 Fax: (508) 616-5522 Email: reg@ibcusa.com Online: www.LifeSciencesInfo.com/PTM | |||||||||||||||
E-mail: | reg@ibcusa.com | |||||||||||||||
Posted by: | James G. Prudhomme | |||||||||||||||
Host: | host-65-124-112-226.ibcusa.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |